RxDoctor Payments DataLook up a doctor →

Matthew Boyce, MD

Neurology · Richmond, VANPI 1952513285

Payments from drug & device makers

$178,260in general payments, 2019–2025

Across 788 payments — averaging $226.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$106K
  • Acadia Pharmaceuticals Inc$26K
  • Acorda Therapeutics, Inc$11K
  • Sage Therapeutics, LLC$10K
  • Amneal Pharmaceuticals LLC$8K
  • H. Lundbeck A S$5K
  • plus $11K from 54 others
$22,080in research payments, 2019–2025

Across 7 payments — averaging $3154.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$22K
  • Medtronic$580

What the payments were for

  • Consulting fees$8,95016%
  • Speaking & faculty fees$30,12754%
  • Travel & lodging$2,0024%
  • Food & beverage$14,39526%
  • Education$2020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)159$106,441
Acadia Pharmaceuticals Inc29$26,388
Acorda Therapeutics, Inc24$11,376
Sage Therapeutics, LLC1$10,435
Amneal Pharmaceuticals LLC31$7,785
H. Lundbeck A S1$4,633
Biogen47$874
AstraZeneca(2 entities)27$767
UCB, Inc.41$760
Novartis43$751
Teva Pharmaceuticals USA, Inc.50$556
Kyowa Kirin, Inc.22$465
MDD US Operations, LLC21$436
Lilly USA, LLC17$379
EMD Serono, Inc.20$356
Genentech USA, Inc.16$356
Eisai Inc.12$353
Boston Scientific9$299
TG Therapeutics, Inc.13$298
Medtronic(2 entities)3$281
Lundbeck LLC16$280
SK Life Science, Inc.10$234
Sunovion Pharmaceuticals Inc.13$222
Sanofi10$213
Jazz Pharmaceuticals Inc.9$208
Johnson & Johnson(2 entities)7$190
Insightec,inc3$175
Banner Life Sciences, LLC7$169
Pfizer7$162
Argenx US, Inc.6$154
Harmony Biosciences LLC7$149
Alnylam Pharmaceuticals Inc.7$131
CSL Behring5$120
Grifols USA, LLC6$113
Neurelis, Inc.7$100
Mallinckrodt Hospital Products Inc.3$94
Supernus Pharmaceuticals, Inc.4$86
Amgen(2 entities)5$80
Neurocrine Biosciences, Inc.5$79
Biohaven Pharmaceutical Holding Company Ltd.3$68
Abbott3$67
Axsome Therapeutics, Inc.3$61
Catalyst Pharmaceuticals, Inc.3$60
Biohaven Pharmaceuticals, Inc.3$58
Merz North America, Inc.2$56
Vanda Pharmaceuticals Inc.2$56
ANI Pharmaceuticals, Inc.2$56
Cycle Pharmaceuticals Inc3$55
Averitas Pharma Inc.3$52
Merz Pharmaceuticals, LLC2$52
Bristol Myers Squibb3$51
Life Molecular Imaging Ltd1$48
Ipsen Biopharmaceuticals, Inc2$45
Otsuka America Pharmaceutical, Inc.2$44
Livanova USA, Inc.2$43
Octapharma USA, Inc.3$42
Avanir Pharmaceuticals, Inc.2$35
Sumitomo Pharma America, Inc.3$35
Greenwich Biosciences, Inc.2$35
Adamas Pharmaceuticals, Inc.2$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$178,260 in reported general payments places this provider in the 90th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$376,017
Medicare patients
804
Services billed
29,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa219$312,949
NuplazidPimavanserin Tartrate36$228,381
GocovriAmantadine Hcl15$75,953
Carbidopa-LevodopaCarbidopa/Levodopa878$29,602
AmantadineAmantadine Hcl113$11,507
Rasagiline Mesylate39$8,696
Propranolol Hcl ErPropranolol Hcl188$8,606
Primidone239$7,347
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone16$4,036
Rivastigmine23$3,670
Entacapone39$3,477
Donepezil Hcl291$3,224
Midodrine Hcl48$2,529
Carbidopa-Levodopa ErCarbidopa/Levodopa48$1,576
Propranolol Hcl69$1,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$7,785$312,949219 claims
Acadia Pharmaceuticals IncNuplazid$26,388$228,38136 claims
MDD US Operations, LLCGocovri$436$75,95315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 neurology providers in Virginia.

Other neurology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →